The Case for Early Founder Exits Why Selling Instead of Multiple Funding Rounds Often Maximizes Value The conventional venture capital playbook suggests that founders should raise successive rounds of funding, scale aggressively, and exit at maximum valuation. However, this narrative…
Private equity is leaving value on the table by keeping “old and proven” and “breakthrough new” in separate silos. On one side sit the classic roll‑up platforms: traditional brick‑and‑mortar businesses with 20‑plus years of operating history, recurring customers, and predictable…
The ‘2026 Tax Cliff’ – Why Belgian Tech Founders may want a US exit… and a US address For years, the “American Dream” for a Belgian tech founder has been a major acquisition by a US strategic buyer or private…
Dear Esteemed Private Equity Partners, Venture Capitalists, Family Office Strategists, and Corporate Development Aficionados, This is a light-hearted yet heartfelt plea from those of us on the other side of the deal table: Please, for the love of EBITDA multiples,…
by Serge Jonnaert Private equity firms and strategic acquirers are increasingly targeting European assets, drawn by favorable valuations, strong sector-specific synergies, and the risk of loss of market access as a result of looming tariff wars. Several significant M&A deals…
Setting M&A Up for Success The Critical Role of Positioning, Messaging, Public Relations, Social Media, and Financial Packages by Serge Jonnaert Mergers and acquisitions (M&A) remain one of the most powerful strategies for companies looking to scale, enter new markets,…
I had the honor to moderate this week’s ‘AI Ethics & Governance’ panel in Los Angeles. It brought together thought leaders and experts for an engaging discussion on the challenges and responsibilities of artificial intelligence with both US and European…
The latest M&A valuation multiples in the health tech sector indicate a slightly optimistic outlook for the remainder of 2024. As of April 2024, the average enterprise value (EV) to sales multiple is 4.8x, up from 4.5x in November 2023.…
BIO2024 – Two sessions related to M&A in biotech, each offering unique perspectives while sharing common themes “From Incubation to Acquisition – The Growth Journey of an Early-Stage Company” centered around Serotiny, a therapeutic discovery company that designs new genes…
The looming specter of the 2024 U.S. elections casts a long shadow over its tech landscape, with few entrepreneurs fully aware of the potential fallout of proposed tax reforms under a possible second Biden term Serge JonnaertCEO & M&A Advisor…